AstraZeneca proceeds for second construction phase of its own high-tech plant at Vorsino Industrial Park, Kaluga Region, which will include full cycle pharmaceutical production facility. Total volume of investments in the construction of the plant will amount to approximately $187 mln, from which more than $100 mln will be allocated for the second phase.
Initially the launch of construction of the full cycle facility was scheduled for 2014, but dynamic project development and also openness and involvement of the regional administration enabled the company to proceed for the second phase ahead of schedule. The launch of production of solid drug formulations is expected for 2016, and the full cycle production capacity will be 500 million tablets per year.
About thirty innovative AstraZeneca drug formulations will be manufactured at the plant to treat diseases in such therapeutic areas as oncology, cardiology, gastroenterology, psychiatry and pulmonology.